Novo A/S
| Private limited company | |
| Industry |
Life science Asset management |
| Founded | 1999 |
| Headquarters | Hellerup, Denmark |
Key people | Sten Scheibye(Chairman) |
| Total assets | DKK 378 billion (2015) |
| Subsidiaries |
Novo Nordisk A/S Novozymes A/S NNIT A/S |
| Website | www.novo.dk |
Novo A/S is a holding company in the Novo Group and is fully owned by the Novo Nordisk Foundation. It is a majority shareholder in Novo Nordisk A/S and Novozymes A/S and manage the Novo Nordisk Foundation's financial assets. Eivind Kolding succeeded Henrik Gürtler as CRO on 1 May 2014.[1] Eivind Kolding left Novo A/S in March 2016 and Kasim Katuy took over as CEO for the organisation.[2]
Investments
- In May 2013, Novo acquired all shares in the pharmaceutical company Xellia.[3]
- In July 2014, Novo acquired all shares in Sonion, a manufacturer of components for the hearing aid industry.[4]
References
- ↑ "Eivind Kolding bliver direktør for Novo A/S" (in Danish). Berlingske. Retrieved 2014-07-17.
- ↑ http://borsen.dk/nyheder/virksomheder/artikel/1/326688/novos_pengetank_faar_ny_topchef.html
- ↑ "Novo køber norsk biotekselskab for fire milliarder kroner" (in Danish). Ingeniøren. Retrieved 2014-07-17.
- ↑ "Novo betaler op mod 4 milliarder kroner for Sonion" (in Danish). Berlingske. Retrieved 2014-07-17.
External links
This article is issued from Wikipedia - version of the 11/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.